Amylyx Pharmaceuticals Dividend
Dividend criteria checks 0/6
Amylyx Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.4% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Earnings per share | US$0.73 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12
An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if AMLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AMLX's dividend payments have been increasing.
Dividend Yield vs Market
| Amylyx Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (AMLX) | n/a |
| Market Bottom 25% (US) | 1.6% |
| Market Top 25% (US) | 4.8% |
| Industry Average (Pharmaceuticals) | 2.4% |
| Analyst forecast in 3 Years (AMLX) | 0% |
Notable Dividend: Unable to evaluate AMLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AMLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate AMLX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AMLX has not reported any payouts.